Last update 09 Dec 2025

DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)

Overview

Basic Info

Drug Type
Synthetic peptide vaccine, Therapeutic vaccine
Synonyms
FLC-Vac
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
NeoplasmsDigestive System DisordersOther Diseases
Active Indication
Fibrolamellar Hepatocellular Carcinoma
Inactive Indication-
Originator Organization
The Sidney Kimmel Comprehensive Cancer Center
Active Organization
The Sidney Kimmel Comprehensive Cancer Center
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
NCT04248569
/ RecruitingPhase 1IIT
A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
100 Clinical Results associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
Login to view more data
100 Translational Medicine associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
Login to view more data
100 Patents (Medical) associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
Login to view more data
100 Deals associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fibrolamellar Hepatocellular CarcinomaPhase 1
United States
The Sidney Kimmel Comprehensive Cancer Center
20 Apr 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04248569 (Pubmed | Nat Med)
Phase 1
Fibrolamellar Hepatocellular Carcinoma
16
jdgfxwjtrz(gnxosqdzfz) = mjkzizgwyl ligvieefcd (owwguysuit )
View more
Positive
24 Nov 2025
NCT04248569 (ASCO2025 | Pubmed | Nat Med)
ManualManual
Phase 1
Fibrolamellar Hepatocellular Carcinoma
DNAJ-PKAc
16
spebttfkur(jizwkfgqdd) = zsyjaelbgf jbrshwydyi (iqykchoybf )
View more
Positive
30 May 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free